17.61
Spyre Therapeutics Inc Borsa (SYRE) Ultime notizie
Will Spyre Therapeutics Inc. stock benefit from AI tech trendsTriple-digit returns - jammulinksnews.com
Is Spyre Therapeutics Inc. a good long term investmentHigh-impact stock picks - PrintWeekIndia
What analysts say about Spyre Therapeutics Inc. stockOutstanding capital growth - Autocar Professional
Spyre Therapeutics Inc. Stock Analysis and ForecastExceptional gains - Autocar Professional
What drives Spyre Therapeutics Inc. stock priceRapid capital growth - jammulinksnews.com
Brokerages Set Spyre Therapeutics, Inc. (NASDAQ:SYRE) Target Price at $53.40 - Defense World
Why Spyre Therapeutics Inc. stock attracts strong analyst attentionMomentum Swing Watchlist - beatles.ru
How Spyre Therapeutics Inc. stock performs during market volatilityPredictable High Return Trades - Newser
What makes Spyre Therapeutics Inc. stock price move sharplyPotential Rocket List - Newser
Here's Why We're Not Too Worried About Spyre Therapeutics' (NASDAQ:SYRE) Cash Burn Situation - Yahoo Finance
This Spyre Therapeutics Insider Reduced Their Stake By 55% - 富途牛牛
Spyre Therapeutics Announces Grants of Inducement Awards - TradingView
GAMMA Investing LLC Purchases New Shares in Spyre Therapeutics, Inc. (NASDAQ:SYRE) - Defense World
Analysts Offer Insights on Healthcare Companies: Sandoz Group Ltd (OtherSDZXF) and Spyre Therapeutics (SYRE) - The Globe and Mail
Spyre Therapeutics: Positive Anti-TL1A Data Brings 2 Program Pathways Forward (SYRE) - Seeking Alpha
Spyre reports results from early stage TL1A antibody trials (SYRE) - Seeking Alpha
Transcript : Spyre Therapeutics, Inc.Special Call - MarketScreener
Spyre Therapeutics Announces Positive Interim Phase 1 Results fo - GuruFocus
Spyre Therapeutics Says Anti-TL1A Antibodies Met Objectives in Interim Phase 1 Study - MarketScreener
Spyre Therapeutics Announces Positive Phase 1 Results - TipRanks
Spyre Therapeutics (SYRE) Advances Clinical Trials with Encouraging Interim Results | SYRE Stock News - GuruFocus
Spyre Therapeutics Announces Positive Interim Phase 1 Results for Two Next-Generation TL1A Antibody Programs, and Provides Clinical Development Updates Expected to Deliver 9 Phase 2 Readouts - PR Newswire
Spyre Therapeutics to Host Conference Call and Webcast to Report - GuruFocus
Spyre Therapeutics to Unveil First Human Trial Data for Revolutionary IBD Antibody Treatment - Stock Titan
Bank of America Corp DE Reduces Stock Holdings in Spyre Therapeutics, Inc. (NASDAQ:SYRE) - Defense World
California State Teachers Retirement System Grows Stake in Spyre Therapeutics, Inc. (NASDAQ:SYRE) - Defense World
UBS AM a distinct business unit of UBS ASSET MANAGEMENT AMERICAS LLC Acquires 22,540 Shares of Spyre Therapeutics, Inc. (NASDAQ:SYRE) - Defense World
Transcript : Spyre Therapeutics, Inc. Presents at Goldman Sachs 46th Annual Global Healthcare Conference 2025, Jun-09-2025 09 - MarketScreener
Apri su Yahoo
|
Apri su Google
|
Aperto in Finviz
|
Apri in MarketWatch
|
Aperto a EDGAR
|
Aperto su Reuters
Capitalizzazione:
|
Volume (24 ore):